Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Teplizumab in the Treatment of Japanese Pediatric and Adult Participants Aged 1 to 34 Years With Stage 2 Type 1 Diabetes: A Multicenter, Randomized, Open-label, Controlled Study.

NCT06791291 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT06791291
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06791291 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Teplizumab in the Treatment of Japanese Pediatric and Adult Participants Aged 1 to 34 Years With Stage 2 Type 1 Diabetes: A Multicenter, Randomized, Open-label, Controlled Study.
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Recruiting
Start date
July 25, 2025
Completion date
March 6, 2028
Enrollment
10 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

type 1 diabetes mellitus